The role of the right valuation method in setting the firm’s break-even price for mpox (and other) vaccines
Critical voices on unfairly high mpox and other vaccine prices open the debate on the ‘right price’ to be paid to private vaccine suppliers. We apply compound real options analysis as a more appropriate valuation method to derive a correct firm’s break-even price. Real option models are better able...
Saved in:
| Main Authors: | Peter-Jan Engelen, Danny Cassimon |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/10/5/e018390.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Innovation and valuation of Chinese born-global firms.
by: Ruize Cai, et al.
Published: (2025-01-01) -
Break-even maturity as a guide to financial distress
by: Colin Ellis
Published: (2014-12-01) -
Debt Capital and Dividend Policy as Complementary Indicators of Firm Valuation
by: Okechukwu Enyeribe Njoku, et al.
Published: (2025-02-01) -
Carbon Footprint, Financial Structure, and Firm Valuation: An Empirical Investigation
by: István Hágen, et al.
Published: (2024-12-01) -
Student study group break-even value and adjustment of the educational program portfolio
by: G. L. Azoev
Published: (2023-06-01)